Akebia Therapeutics Inc. (NASDAQ:AKBA) finished Wednesday with a subtraction of -$0.01 to close at $2.94, a downside of -0.34 percent. An average of 1,246,020 shares of common stock have been traded in the last five days. There was a gain of $0.19 in the past week. The last 20 days have seen an average of 1,744,290 shares traded, while the 50-day average volume stands at 2,209,690.
AKBA stock has increased by 6.91% in the last month. The company shares reached their 1-month lowest point of $2.70 on 09/16/21. With the stock rallying to its 52-week high on 02/08/21, shares of the company touched a low of $2.09 and a high of $5.14 in 52 weeks. In spite of this, the price is down -42.80% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
44 days have passed since Akebia Therapeutics Inc. (AKBA) last reported insider trading activity. Burke Steven Keith, who is SVP, Chief Medical Officer, most recently acquired $1,042 shares at $2.83 per share on Aug 31. In this transaction, the insider spent $2,949. Director, GILMAN STEVEN C, disposed of 4,567 shares at a price of $3.32 on Jun 07. The insider now owns more than $15,163 worth of shares. Prior to that, CEO and President Butler John P. went on to Sale 49,990 shares at $3.40 each on Mar 01. An amount of $169,771 was transacted.
Akebia Therapeutics Inc. (AKBA) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 1.63. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.30, the price-to-book (PB) ratio at 2.72.
The quick ratio of Akebia Therapeutics Inc. for the three months ended June 29 was 1.80, and the current ratio was 2.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.55 and a total debt to equity ratio of 0.55 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 31.20% against a 5-year average of 70.5%. Akebia Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -76.98%. Its gross profit as reported stood at $114.93 million compared to revenue of $295.31 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Akebia Therapeutics Inc.’s return on assets was -46.80%, compared to -38.1% over the last five years. In the past year, the return on investment has been -109.40%, and the 5-year average is -77.4%. Meanwhile, the return on equity (ROE) for the past 12 months has been -125.60% and the 5-year average holds at -85.0%. For the broader industry, ROE averaged -68.79 over the past year.
The analyst consensus anticipated Akebia Therapeutics Inc.’s latest quarter earnings to come in at -$0.32 per share, but it turned out to be -$0.51, a -59.40% surprise. For the quarter, EBITDA amounted to -$69.84 million. Shareholders own equity worth $174.54 million.
From a technical analysis perspective, let’s take a brief look at Akebia Therapeutics Inc. (AKBA) price momentum. RSI 9-day as of the close on 13 October was 58.84%, suggesting the stock is Neutral, with historical volatility in this time frame at 27.63%.
As of today, AKBA’s price is $2.89 +6.91% or $0.19 from its 5-day moving average. AKBA is currently trading +5.76% higher than its 20-day SMA and -15.76% lower than its 100-day SMA. However, the stock’s current price level is +14.40% above the SMA50 and +4.63% above the SMA200.
The stochastic %K and %D were 58.97% and 47.29%, respectively, and the average true range (ATR) was 0.13. With the 14-day stochastic at 58.97% and the average true range at 0.14, the RSI (14) stands at 55.20%. The stock has reached 0.10 on the 9-day MACD Oscillator while the 14-day reading was at 0.07.
Cantor Fitzgerald launched coverage on Akebia Therapeutics Inc. (NASDAQ: AKBA) in its analyst report released on March 08, 2021. The firm assigned the stock a an Overweight rating.The consensus rating for Akebia Therapeutics Inc. (AKBA) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell AKBA, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is AKBA’s price target for the next 12 months?
Analysts predict a range of price targets between $2.76 and $10.00, with a median target of $6.50. Taking a look at these predictions, the average price target given by analysts for Akebia Therapeutics Inc. (AKBA) stock is $6.63.